MedX Launches Its DermSecure™ Telemedicine Platform
Sep. 04, 2018
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Sep 4, 2018--MedX Health Corp. (“MedX”) (TSX-V:MDX) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with Electronic Medical Record (EMR’s) systems. Its development roadmap includes the addition of features and functions to the DermSecure™ platform that will be released on a regular basis.
“DermSecure™ is a secure telemedicine platform, coupled with MedX’s innovative imaging technology, SIAscopy, that will provide dermatologists and patients access to the most advanced mole and lesion rapid assessment system available in the marketplace. This technology will be deployed in medical clinics to provide MedX’s non-invasive skin scanning technology to physicians who will be able to have a dermatologist assess their patients’ suspicious moles or lesions remotely,” said Scott Spearn, President of MedX. “DermSecure™ clearly offers great benefits to patients and primary care physicians by working with dermatologists, leveraging their skills. DermSecure™ is a Software-as-a-Service revenue model, with recurring revenue growth – a key development for MedX,” noted Mr. Spearn.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Company’s sales strategies.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005830/en/
CONTACT: MedX Health Corp
Scott Spearn, 905-670-4428
Deborah Thompson, 416-918-9551
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH ONCOLOGY GENERAL HEALTH
SOURCE: MedX Health Corp.
Copyright Business Wire 2018.
PUB: 09/04/2018 03:49 PM/DISC: 09/04/2018 03:49 PM